A highly specific SpCas9 variant is identified by in vivo screening in yeast
A Casini, M Olivieri, G Petris, C Montagna… - Nature …, 2018 - nature.com
Despite the utility of CRISPR–Cas9 nucleases for genome editing, the potential for off-target
activity limits their application, especially for therapeutic purposes,. We developed a yeast …
activity limits their application, especially for therapeutic purposes,. We developed a yeast …
A highly specific SpCas9 variant is identified by in vivo screening in yeast.
A Casini, M Olivieri, G Petris, C Montagna… - Nature …, 2018 - europepmc.org
Despite the utility of CRISPR-Cas9 nucleases for genome editing, the potential for off-target
activity limits their application, especially for therapeutic purposes 1, 2. We developed a …
activity limits their application, especially for therapeutic purposes 1, 2. We developed a …
A highly specific SpCas9 variant is identified by in vivo screening in yeast
A Casini, M Olivieri, G Petris, C Montagna… - Nature …, 2018 - go.gale.com
Despite the utility of CRISPR-Cas9 nucleases for genome editing, the potential for off-target
activity limits their application, especially for therapeutic purposes [1, 2]. We developed a …
activity limits their application, especially for therapeutic purposes [1, 2]. We developed a …
A highly specific SpCas9 variant is identified by in vivo screening in yeast
A Casini, M Olivieri, G Petris, C Montagna… - NATURE …, 2018 - cris.fbk.eu
Despite the utility of CRISPR-Cas9 nucleases for genome editing, the potential for off-target
activity limits their application, especially for therapeutic purposes. We developed a yeast …
activity limits their application, especially for therapeutic purposes. We developed a yeast …
[引用][C] A highly specific SpCas9 variant is identified by in vivo screening in yeast
A Casini, M Olivieri, G Petris, C Montagna… - Nature …, 2018 - cir.nii.ac.jp
A highly specific SpCas9 variant is identified by in vivo screening in yeast
A Casini, M Olivieri, G Petris… - Nature …, 2018 - pubmed.ncbi.nlm.nih.gov
Despite the utility of CRISPR-Cas9 nucleases for genome editing, the potential for off-target
activity limits their application, especially for therapeutic purposes. We developed a yeast …
activity limits their application, especially for therapeutic purposes. We developed a yeast …
[HTML][HTML] A highly specific SpCas9 variant is identified by in vivo screening in yeast
A Casini, M Olivieri, G Petris, C Montagna… - Nature …, 2018 - ncbi.nlm.nih.gov
Despite the utility of CRISPR-Cas9 nucleases for genome editing, the potential for off-target
activity limits their application, especially for therapeutic purposes 1, 2. We developed a …
activity limits their application, especially for therapeutic purposes 1, 2. We developed a …
A highly specific SpCas9 variant is identified by in vivo screening in yeast
A Casini, M Olivieri, G Petris, C Montagna… - NATURE …, 2018 - iris.unitn.it
Despite the utility of CRISPR-Cas9 nucleases for genome editing, the potential for off-target
activity limits their application, especially for therapeutic purposes. We developed a yeast …
activity limits their application, especially for therapeutic purposes. We developed a yeast …
[PDF][PDF] A highly specific SpCas9 variant is identified by in vivo screening in yeast
A Casini, M Olivieri, G Petris, C Montagna, G Reginato… - Nat Biotechnol, 2018 - iris.unitn.it
Despite the utility of CRISPR-Cas9 nucleases for genome editing, the potential for off-target
activity limits their application, especially for therapeutic purposes1, 2. We developed a …
activity limits their application, especially for therapeutic purposes1, 2. We developed a …
A highly specific SpCas9 variant is identified by in vivo screening in yeast.
A Casini, M Olivieri, G Petris, C Montagna… - Nature …, 2018 - europepmc.org
Despite the utility of CRISPR-Cas9 nucleases for genome editing, the potential for off-target
activity limits their application, especially for therapeutic purposes 1, 2. We developed a …
activity limits their application, especially for therapeutic purposes 1, 2. We developed a …